68Ga-PSMA-11
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
PCA
Conditions
PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET, Diagnostic Imaging, Elevated PSA, Positron Emission Tomography, Prostate Biopsy, Carcinoma of the Prostate
Trial Timeline
Aug 18, 2025 → Nov 1, 2026
NCT ID
NCT07052214About 68Ga-PSMA-11
68Ga-PSMA-11 is a phase 3 stage product being developed by Telix Pharmaceuticals for PCA. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07052214. Target conditions include PCA, Prostate Cancer, Prostatic Neoplasm.
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07052214 | Phase 3 | Recruiting |
| NCT05847348 | Phase 3 | Recruiting |